Svetlana Mojsov, Ph.D.Research Associate Professor
Laboratory of Cellular Physiology and Immunology
Dr. Mojsov’s long-standing interests have been in understanding how peptides and small proteins regulate physiological processes in healthy and disease states. She has applied her expertise in the chemical synthesis of peptides and small proteins to a wide range of studies, starting with the discovery of glucagon-like peptide 1 (GLP-1) and its key role in insulin secretion and glucose metabolism. Based on Dr. Mojsov’s work, Novo Nordisk developed a GLP-1 analogue as a new therapeutic agent for type 2 diabetes, recently approved for use in Europe, Japan, China and the United States under the trade name Victoza.
Most recently, Dr. Mojsov has collaborated with members of the Steinman laboratory on developing a proteomic approach to identify
the peptide repertoire presented by the major histocompatibility complex on dendritic cells after immunizations with proteins that
are specifically delivered to dendritic cells. This work is part of the effort to develop dendritic cell-based vaccines against HIV and other infectious agents.